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Abstract
Background: To assess the factors affecting the incidence of radiation-induced dermatitis in breast cancer patients
treated with adjuvant 3 D conformal radiotherapy by the analysis of dosimetry and topical treatments.
Methods: Between September 2002 and July 2009, 158 breast cancer patients were treated with adjuvant 3 D
conformal radiotherapy after undergoing surgery. Before November 2006, 90 patients were subjected to
therapeutic skin care group and topical corticosteroid therapy was used for acute radiation dermatitis. Thereafter,
68 patients received prophylactic topical therapy from the beginning of radiotherapy. The two groups did not
differ significantly in respect of clinical and treatment factors. Furthermore, the possible mechanisms responsible for
the effects of topical treatment on radiation-induced dermatitis were investigated in vivo.
Results: The incidence of radiation-induced moist desquamation was 23% across 158 patients. Higher volume
receiving 107% of prescribed dose within PTV (PTV-V107%; >28.6%) and volume receiving 110% of prescribed dose
within treated volume (TV-V110%; > 5.13%), and no prophylactic topical therapy for irradiated skin, were associated
with higher incidence of acute radiation dermatitis. The protective effect of prophylactic topical treatment was
more pronounced in patients with TV-V110% > 5.13%. Furthermore, using irradiated mice, we demonstrated that
topical steroid cream significantly attenuated irradiation-induced inflammation, causing a decrease in expression of
inflammatory cytokines and TGF-beta 1.
Conclusion: TV-V110% > 5.13% may be an important predictor for radiation induced dermatitis. Prophylactic topical
treatment for irradiated skin can significantly improve the tolerance of skin to adjuvant radiotherapy, especially for
patients with higher TV-V110%.
Background
Radiotherapy (RT) is commonly used as an adjuvant
modality in the treatment of breast cancer [1,2]. Adju-
vant chest wall irradiation for high risk breast cancer
patients receiving modified radical mastectomy (MRM),
and whole breast irradiation for patients after a breast-
conserving surgery (BCS), are known to decrease
loco-regional recurrence and improve overall survival.
However, acute and chronic toxicities have been noted
in patients treated with adju v a n tb r e a s to rc h e s tw a l l
RT, including skin (30~40%), lung (3/%) and heart toxi-
city (1.5%) [3-5]. Traditionally, adjuvant RT for breast
cancer patients after surgery is delivered using conven-
tional tangential fields. An important concern with
conventional RT is dose inhomogeneity resulting in irra-
diation of more normal tissue. In recent years promising
RT techniques have been developed for various malig-
nancies, including three-dimensional conformal radio-
therapy (3D-CRT), IMRT and tomotherapy. These have
improved dose homogeneity and conformity, and are
associated with relatively low risks for toxicity compared
with conventional RT technique [6-8].
RT-induced skin toxicity is a prominent clinical pro-
blem affecting the majority of breast cancer patients
receiving adjuvant RT and can lead to temporary or per-
manent cessation of treatment. Severe skin reactions
may be painful, lead to localized or occasionally sys-
temic infection, and cause permanent scarring. The inci-
dence of RT-related toxicity may be reduced by
refinements in radiation techniques, such as improving
dose conformity and dose homogeneity within the irra-
diated area. It is reported that breast IMRT could
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the irradiated skin by delivering a more homogenous
dose of radiation through the breast and efficiently
removing the radiation hot spots [9,10]. Accordingly,
better understanding of dosimetric parameters, which
m a yb er e l a t e dt oa c u t es k i nt o x i c i t yi nt h e s ew o m e n ,
will help to improve treatments in the future. Therefore,
we present an analysis of the correlation between radio-
therapy parameters and acute skin toxicity in breast can-
cer patients treated with 3D-CRT at our institution.
It is recommended that skin in the irradiated area be
kept clean and free from trauma. Many physicians com-
mence topical therapy at the clinical onset of radiation
dermatitis but there is no consensus regarding the most
appropriate timing or agents for topical therapy in such
instances. Recently, some agents including creams con-
taining urea and steroid, have been investigated and
showed significant effects to reduce radiation induced
dermatitis [11-13]. However, the treatment of acute
radiation dermatitis still varies between different oncol-
ogy center. Therefore, we evaluated whether prophylac-
tic topical therapies can decrease the incidence of
radiation-induced skin toxicity in a clinical setting as
well as in vivo.
Methods
Characteristics of patients and treatment
This retrospective study was approved by the Institu-
tional Review Board, and a waiver of informed consent
was obtained. The patient data consisted of women who
had undergone surgery for breast cancer followed by
adjuvant 3D-conformal radiotherapy in our department
between September 2002 and July 2009. Patients treated
before November 2006 did not receive topical therapy
for the skin until the onset of radiation dermatitis (ther-
apeutic skin care group). Patients treated after this date
underwent prophylactic topical therapy, including ster-
oid cream (0.1% mometasone) and barrier film spray
(3M™Cavilon No-sting Barrier Film) (prophylactic skin
care group). Prophylactic medication was applied to the
treatment field every three days from the start of RT
[12]. In general, adjuvant 3D-CRT was prescribed for
50.4 Gy of external beam radiotherapy in 28 fractions. If
required, adjuvant chemotherapy was performed
sequentially rather than concurrently with radiotherapy
in these patients (105 patients). Among these irradiated
patients, there were 92 patients received hormone ther-
apy. The Radiation Therapy Oncology Group (RTOG)
scale was used to evaluate acute skin toxicity during
radiation treatment at weekly clinical examinations,
which continued for three weeks after the end of radio-
therapy. Grade 2 skin toxicity is described in the RTOG
Acute Morbidity Scale as, “tender or bright erythema,
patchy moist desquamation/moderate edema, and Grade
3a s ,“confluent moist desquamation other than skin
folds, pitting edema”. The correlation between acute
radiation dermatitis and examined risk factors was cal-
culated as the percentage of patients with moist desqua-
mation (including grade 2 and grade 3 RTOG acute skin
toxicity).
Radiotherapy planning
Radiotherapy was planned using the Eclipse Planning
System (version 7.1.35, Varian Medical System, Palo
Alto, CA), and treatment was delivered using Varian
21EX. All patients were treated with 3 D conformal
radiotherapy. For radiation therapy with 3D-CRT, a cus-
tomized immobilization device was developed which
encompassed the upper extremities, head, neck and
chest, to minimize variability in the daily setup. The
clinical target volume (CTV) was contoured on the indi-
vidual axial CT slices with 5 mm slice thickness of each
patient. The CTV was expanded by 10 mm, but within
3 mm of the skin surface, to create the planned target
volume (PTV). Treatment plans were developed by
applying tangential photon fields set up isocentrically,
with or without individually weighted segmental fields
superimposed on the tangential fields and 1-2 coplanar,
different gantry angle fields. Wedges were used in
almost all cases. Our planning goals were to provide a
homogenous PTV dose of 50.4 Gy, while minimizing
the dose delivered to the lung, heart and contralateral
breast. Furthermore, to evaluate the effects of dose inho-
mogeneity on acute skin toxicity, we analyzed several
dosimetric factors including the planning target volume
(PTV), PTV-V107% (percent volume receiving 107% of
prescribed dose within PTV) and TV-V110% (percent
volume receiving 110% of prescribed dose within treated
volume (TV)) to identify the hot spot area within and
outside the target. The definition of treated volume is
that volume enclosed within the prescribed dose, and
the areas receiving excessive dose, especially >10% of
prescribed dose, are known as radiation hot spot. Figure 1
shows the isodose distribution of a representative patient,
illustrating the area of PTV-V107% and TV-V110% related to
the location of moist desquamation.
Statistical methods
The c
2 test was utilized to compare acute skin toxicity
between different sample groups, and to analyze associa-
tions between acute toxicity, dosimetric parameters and
clinical characteristics. Statistical significance was
assumed at p < 0.05.
Mice, radiation and topical therapy
Thirty male BALB/c mice, aged between 8 and 10 weeks
old, were purchased from the National Science Council,
Taiwan. Protocols relating to animal experimentation
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Laboratory Animal Center. For irradiation experiments,
anesthetized mice restrained in modified Perspex tubes
and covered with a 0.3 cm bolus, received a irradiation
dose of 15 Gy in a single fraction to the skin by 6 MeV
electron from a linear accelerator [14]. Unirradiated
mice were subjected to the same conditions but were
not exposed to the radiation source (sham-irradiation).
For topical treatment the mice were divided into three
groups: C-mice, which received no topical treatment;
S-mice, treated with topical steroid cream (0.1% mome-
tasone) (cream was applied on the irradiated skin imme-
diately after initial treatment and once every two days
after irradiation); and F-mice, which received topical
treatment by Barrier Film Spray (topical film spray was
applied on the irradiated skin immediately after initial
treatment and once every two days after irradiation).
RNA isolation and real-time RT-PCR
At the indicated times after irradiation, three mice from
each group were sacrificed by cervical dislocation, and
irradiated skin was dissected and stored at -80°C pend-
ing analysis [15]. Specific Assay-on-Demand Gene
Expression Assay mixes (including primer and Taqman
MGB probes) for IL-1a/b,I L - 6 ,T N F - a and TGF-b1
were used for real-time PCR (Applied Biosystems,
Foster, CA, USA). The mRNA (2 μg) was reverse-tran-
scribed with random primer to obtain the first cDNA
strand. The first strand cDNA was amplified through
40 cycles (95°C for 15 s and 60°C for 1 min) with the
TaqMan Universal PCR Master mix and the specific
Assay-on-Demand Gene Expression Assay mix for each
gene according to the manufacturer’s instructions.
Immunoblotting
Equal amounts of protein were loaded on to SDS-PAGE
gels. After electrophoresis, the proteins were transferred
to nitrocellulose membranes. The membranes were
incubated with antibodies specific for TGF-b1, IL-6,
MCP-1 and COX-2 (Santa Cruz Biotechnology, Inc), fol-
lowed by incubation with horseradish peroxidase-conju-
gated secondary antibodies. Signals were detected using
enhanced chemiluminescence. To normalize protein
loading, the membrane was re-probed with mouse anti-
r-tubulin antibody (1:1000).
Immunochemical staining
Cellular aspects of inflammation were measured in skin
tissue samples using immunochemical staining. Experi-
mental and control mice were sacrificed by cervical dis-
location 20 days after exposure to 15 Gy irradiation.
The tissues were fixed in 10% buffered formalin, paraf-
fin-embedded and sectioned at an average thickness of
5 μm. Briefly, samples were incubated overnight with
goat anti-mouse TGF-b1 antibody (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA) diluted 1:20 in 0.01
MR P M Ia tr o o mt e m p e r a t u r e .A f t e rw a s h i n gt h r e e
times with PBS, the sections were incubated with bioti-
nylated anti-goat IgG (1:100) for 10 min followed by
peroxidase-avidin staining. Samples were washed with
PBS, followed by addition of 3-amino-9 ethylcarbazole.
Results
Patients and treatment
One hundred and fifty-eight patients met the study cri-
teria and completed the planned course of treatment.
Ninety patients underwent chest wall irradiation and
TV-V110%
Figure 1 3D-conformal radiation therapy isodose distributions are presented for a representative patient.
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a g e( ± S D )o ft h eo v e r a l ls t u d yp o p u l a t i o nw a s5 0±1 1
(range 24-86) years. The incidence of moist desquama-
tion was 23% of the total study population, 26% for
patients who underwent chest wall irradiation and 19%
for those that received whole breast irradiation. Among
37 patients developed moist desquamation,34 patients
appeared grade 2 and 3 had grade 3 radiation dermatitis.
The details of the treatment parameters are listed in
Table 1. The median PTV-V107% and TV-V110% within
the 158 patients were 28.6% and 5.13% respectively. In
comparison of dosimetric parameters between the
2 groups, the mean dose, target coverage and dose inho-
mogeneity did not differ significantly between patients
receiving chest wall irradiation or whole breast irradia-
tion (Table 1). Furthermore, we divided the 158 patients
into the therapeutic skin care group (comprising
80 patients) and the prophylactic skin care group (com-
prising 78 patients, including 35 treated with steroid
ointment and 43 treated with barrier film spray). As
shown in Table 2, dose inhomogeneity (indicated by
PTV-V107% and TV-V110%) and surgery type did not dif-
fer significantly between the two groups, but the inci-
dence of moist desquamation was significantly greater in
the therapeutic skin care group than in the prophylactic
skin care group (30% versus 16.6%, p=0.048). Further-
more, within the prophylactic skin care group there was
no statistical difference in the incidence of radiation der-
matitis between those patients treated with topical ster-
oid cream and those treated with barrier film spray
(14.2% versus 18.6%, p=0.61).
Acute toxicity
Univariate analysis of the data demonstrated that higher
PTV-V107% (>28.6%), higher TV-V110% (> 5.13%) and no
prophylactic topical therapy for irradiated skin, were sig-
nificantly associated with moist desquamation (Table 3),
and TV-V110% still possessed predictive power on the
incidence of radiation dermatitis in multivariate analysis
(Table 3B). Therefore, we used the median of TV-V110%
as a cut-off value to divide the 158 patients into group I
(comprising 79 patients with TV-V110%≤ 5.13%) and
group II (comprising 79 patients with TV-V110% >
5.13%), and further analyzed the risk factors associated
with higher grade skin toxicity for each group. We
Table 1 Clinical and treatment characteristics of patients
Total MRM BCS P value
Patients (No) 158 90 68
Age
Mean±SD (y/o) 50 ± 11 56 ± 11 48 ± 10
Range 24-86 26-86 24-78
Acute skin toxicity
Grade 2 34 23 11 0.27
Grade 3 3 1 2
CTV
Volume (c.c) 192 ± 59 169 ± 53 226 ± 63
D mean (Gy) 53.2 53.1 53.3
D median (Gy) 53.9 54.5 53.5
V100% (%) 98 98 99
PTV
Volume (c.c) 413 ± 113 345 ± 102 504 ± 124
D mean (Gy) 52.5 52.5 52.5
D median (Gy) 53.1 53.0 53.0
V100% (%) 94 93 95
PTV-V107 (Median; cc) 101 81 132
PTV-V107%,
Median (%) 28.6 24.5 31.5
>Median (28.6) (No) 79 40 39
< = Median (No) 79 50 29 0.11
TV-V110 (Median; cc) 35 32 36
TV-V110%
Median (%) 5.13 5.59 4.37
>Median (5.13) (No) 79 48 31
< = Median (No) 79 42 37 0.33
Abbreviation: MRM= modified radical mastectomy, BCS= breast-conserving
surgery Dmean = mean received dose for target; Dmedian = median received
dose for target.
V100% = percent volume receiving the prescribed dose.
PTV-V107% = percent volume receiving 107% of prescribed dose within PTV.
Treated volume (TV) = the tissue volume which received the prescribed dose.
TV-V110% = percent volume receiving 110% of prescribed dose within TV.
Data are presented as mean with standard deviation.
Table 2 Treatment and dosimetry characteristics of
patients between the two groups
Therapeutic
skin care
Prophylactic
skin care
P
value
Patients (No) 80 78
Surgery type
MRM 45 45
BCS 35 33 0.85
PTV volume
>Median (No) 36 43
< = Median (No) 44 35 0.20
Moist desquamation
(grade 2+grade 3)
Yes 24 13
No 56 65 0.048
PTV-V107%,
>Median (No) 38 41
< = Median (No) 42 37 0.52
TV-V110%
>Median (No) 40 39
< = Median (No) 40 39 1
Abbreviation:
PTV-V107% = percent volume receiving 107% of prescribed dose within PTV.
Treated volume (TV) = the tissue volume which received the prescribed dose.
TV-V110% = percent volume receiving 110% of prescribed dose within TV.
Chen et al. BMC Cancer 2010, 10:508
http://www.biomedcentral.com/1471-2407/10/508
Page 4 of 9found no significant association between the incidence
of acute skin toxicity and surgery type, PTV-V107% and
prophylactic skin care or not for group I (Table 4A). In
group II (patients with TV-V110% > 5.13%), prophylactic
topical therapy significantly decreased the incidence of
higher grade skin toxicity (p=0.008) (Table 4B).
Effects of topical treatment on the radiation-induced
inflammatory mediator
Real-time RT-PCR was utilized to quantify the expres-
sion of cytokines induced by radiation and changes in
expression after topical treatment. Low expression levels
were noted in unirradiated control mice and there were
no significant changes in expression after topical treat-
ment (unirradiated F-mice and S-mice). Irradiation
(15 Gy) induced a significant increase in the mRNA
levels of the cytokines detected in the experimental
groups compared with the unirradiated group after 24
h. Treatment with steroid cream significantly attenuated
the increase of pro-inflammatory cytokines in cutaneous
tissues; barrier film spray had no effect (Figure 2a).
Western blotting of irradiated skin specimens 24 h after
irradiation was used to examine the expression of COX-
2, IL-6 and TGF-b1, which are important mediators of
radiation-induced inflammation. Topical steroid cream
decreased radiation-induced increases in COX-2, IL-6
and TGF-B1expression but barrier film spray had no
effect (Figure 2b). Furthermore, analysis of specimens
seven days after irradiation demonstrated that both topi-
cal treatments alleviated the RT-induced inflammatory
response, and that steroid cream had a greater effect
than barrier film spray (Figure 3a &3b).
Effects of topical treatment on the radiation-induced
expression of inflammatory response by immunochemical
staining
TGF-b1 has been reported as an important predictive bio-
logical marker for RT-induced inflammation and fibrosis
[16]. Therefore, we examined TGF-b1 activity by immuno-
chemical analysis under various conditions. As shown in
Figure 4, very low levels of TGF-b1 were observed in uni-
rradiated murine skin tissues for each group. Twenty days
after exposure to 15 Gy, a pronounced increase in TGF-b1
immunoreactivity was observed in these tissues. A combi-
nation of irradiation with topical treatment resulted in a
decrease in TGF-b1 immunoreactivity compared with
radiation treatment alone, and the effect was more appar-
ent in those treated with steroid cream than in those trea-
ted with barrier film spray.
Discussion
Postoperative radiotherapy has become an integral part
of the complex treatment of breast cancer. The risk of
Table 3 Univariate analysis to determine factors
associated with higher grade radiation- induced
dermatitis for 158 irradiated patients
Variables P value
Surgery type
(MRM versus BCS)
0.266
Hormone therapy
(Yes versus no)
0.120
PTV volume
(< = median versus >
median)
0.112
PTV-V107%
(< = median versus >
median)
0.039
TV-V110%
(< = median versus >
median)
0.000
Skin care
(prophylactic versus
therapeutic)
0.048
Multivariate analysis to determine factors associated with higher
grade radiation- induced dermatitis for 158 irradiated patients
Variables Odd
ratios
95%
confidence
interval
p
Surgery type 1.4832 0.6449-3.4107 0.3536
PTV volume 1.0637 0.4846-2.3347 0.8776
PTV-V107% 0.8488 0.4014-1.7951 0.6680
TV-V110% 0.1037 0.0305-0.3528 0.0003
Skin care 1.8679 0.9025-3.8662 0.0923
Abbreviation:
MRM= modified radical mastectomy
BCS= breast conservative surgery
Table 4 Univariate analysis to determine factors
associated with higher grade radiation- induced
dermatitis for 79 irradiated patients with TV-V110% <=
Median
Variables P value
Surgery type
(MRM versus BCS)
0.577
PTV volume
(< = median versus > median)
0.701
PTV-V107%
(< = median versus > median)
0.210
Skin care
(prophylactic versus therapeutic)
0.547
Univariate analysis to determine factors associated with higher
grade radiation- induced dermatitis for 79 irradiated patients with
TV-V110% >Median
Variables P value
Surgery type
(MRM versus BCS)
0.491
PTV volume
(< = median versus >median)
0.183
PTV-V107%
(< = median versus >median)
0.700
Skin care
(prophylactic versus therapeutic)
0.008
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tion exposure of the organ at risk. The development of
appropriate methods for preventing and treating estab-
lished radiation-induced skin toxicity would be helpful
for approximately 25% of breast cancer patients who
develop moist desquamation or ulceration of the irra-
diated chest wall/breast skin [9,10]. At present, there are
still no established methods for decreasing radiation
dermatitis. In the present study, we evaluated the effects
of dosimetry and prophylactic skin care on radiation-
induced skin toxicity.
In recent years, 3D-CRT, IMRT and tomotherapy have
become promising treatments to improve conformality
and dose homogeneity for adjuvant RT treatment of
breast cancer. However, there have been few studies
concerning the correlation between dosimetric para-
meters and the incidence of radiation-induced skin toxi-
city. In the present study, we demonstrated that a larger
volume receiving >53.9 Gy within PTV (PTV-V107%) and
> 55.4 Gy within treated volume (TV-V110%) were signif-
icant predictors of RT- induced skin toxicity. The simi-
lar percentages of patients with higher PTV-V107% and
Figure 2 Effect of topical treatments including steroid and barrier film spray on pro-inflammatory cytokines in skin and subcutaneous
tissues after irradiation by real-time RT-PCR. The mRNA levels of the cytokines TNF-a, IL-6, IL-1a/b and TGF-b were quantified by real-time
RT-PCR. RNA were extracted from murine tissues (a) 24 h; (b) 7 days after irradiation. The results were normalized to the value of irradiated mice.
The y-axis shows the RNA ratio of each target gene divided by that in the irradiated mice. Columns, means of 3 separate experiments; bars, SD.
*, P < 0.05. Twenty- four hours after irradiation, topical steroid cream significantly attenuated the increase of pro-inflammatory cytokines in
cutaneous tissues, but barrier film spray had no effect Furthermore, both topical treatments alleviated the RT-induced inflammatory response,
and that steroid cream had a greater effect than barrier film spray 7 days after irradiation.
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significantly affect the incidence of radiation dermatitis.
In addition to dose inhomogeneity, we found that pro-
phylactic skin care (steroid cream and barrier film spray)
provided significant protection from radiation-induced
dermatitis. There are still no well established prophylac-
tic treatments to prevent radiation skin toxicity despite
some agents are reported to reduce radiation induced
dermatitis, including topical vitamin C, creams contain-
ing urea and steroid [11-13,17-19]. Topical corticoster-
oid therapy was reported to significantly reduce acute
radiation dermatitis by 2 randomized trials, but Potera
[18] demonstrated that topical hydrocortisone had no
discernible benefit in preventing dermatitis. In the pre-
sent study, all patients received chest wall/breast irradia-
tion with the same prescribed dose. The results of our
study demonstrate that prophylactic skin care decreases
radiation-induced dermatitis, especially in patients with
larger TV-V110%. For patients in who with TV-V110%
was less than 5.13%, prophylactic skin care provided no
significant benefit. Accordingly, we suggested that pro-
phylactic skin care may be helpful preventing higher
dose radiation-induced dermatitis in clinics.
Clinically, cutaneous inflammation after irradiation of
normal tissue can lead to both temporary and persistent
complications. In mice, early radiation dermatitis usually
peaks at 20 days [20]. Several studies have implicated
cytokine-mediated inflammation in radiation-induced
toxicity [20-22]. RT-induced production of pro-inflam-
matory cytokines including IL-1b,T N F - a,T G F - b1a n d
IL-6 have been shown to contribute significantly to the
complications associated with radiotherapy [23-26].
Early overproduction of both pro-inflammatory cyto-
kines and pro-fibrogenic TGF-b1 during radiotherapy in
animal studies suggests a role in the development of
acute and late radiation toxicities [16]. Furthermore,
TGF-b1 is the master switch cytokine, which once acti-
vated after radiation treatment promotes a chain of cel-
lular events that result in radiation-induced fibrosis [27].
In humans, some clinical reports have shown changes in
the plasma concentrations of TGF-b1 and IL-6 proteins
during radiotherapy, suggesting that these variations
could identify patients at risk of radiation toxicity
[28,29]. Several studies have also reported COX-2 to be
an important gene mediating the subsequent inflamma-
tion [30-32]. Such data indicate that the RT-induced
response in vivo is associated with increased TGF-b1
and COX-2 expression, and inflammatory cytokines.
Therefore, we assessed the potential of treatment with
topical steroid cream to mitigate skin toxicity caused by
irradiation in animal studies. Topical steroid cream
decreased the RT-induced inflammatory response, caus-
ing a reduction in levels of the pro-inflammatory cyto-
kines IL-1a/b,T N F - a, TGF-ß1, IL-6 and MCP-1.
Prophylactic barrier film spray had no effect on the pro-
duction of early inflammatory cytokines after radiation
exposure in mice. However, analysis of inflammatory
cytokine RNA, TGF-b1a n dC O X - 2p r o t e i ne x p r e s s i o n
one week after irradiation, and TGF-b1immunochemical
staining 20 days after irradiation, demonstrated that
both topical steroid and barrier film spray did have an
(a)
C        RT    RT+S   RT+F
IL 6 IL-6
TGF-β1
COX 2 COX-2
MCP-1
β actin β-actin
(b)
C        RT    RT+S   RT+F
IL-6
TGF-β1
COX-2
MCP-1
β-actin
Figure 3 Effect of topical treatments including steroid and
barrier film spray on pro-inflammatory cytokines in skin and
subcutaneous tissues after irradiation by Western blotting
analysis. Expressions of COX-2, IL-6, TGF-b1 and MCP-1protein in
irradiated murine skin and subcutaneous tissue with or without
topical treatment including steroid cream and barrier film spray.
Proteins were extracted form murine tissues (a) 24 h; (b) 7 days after
irradiation. (C, control; RT, irradiation; RT+S, steroid cream plus
irradiation; RT+F, barrier film spray plus irradiation). Triplicate
experiments were performed for the analysis. Twenty- four hours
after irradiation, topical steroid cream significantly attenuated the
increase of COX-2, IL-6, TGF-b1 and MCP-1 in cutaneous tissues, but
barrier film spray had no effect Furthermore, both topical treatments
alleviated the RT-induced response 7 days after irradiation.
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on our clinical data and experiments in vivo, we suggest
that prophylactic topical steroid treatment inhibits RT-
induced inflammation, leading to decreased radiation
dermatitis. The mechanism responsible to barrier film
spray- induced decrease in radiation dermatitis might be
to decrease skin trauma and skin irritation. However,
the effects of barrier film spay on irradiated skin and
the underlying mechanisms still need further
investigation.
Conclusions
Our results suggest that dose inhomogeneity as mea-
sured by PTV-V107% and TV-V110% have a significant
impact on radiation-induced dermatitis. By multivariate
analysis, TV-V110% > 5.13% is an important predictor of
the incidence of moist desquamation. In addition, pro-
phylactic topical treatment for irradiated skin could sig-
nificantly improve the tolerance of skin to adjuvant
radiotherapy, especially for patients with higher TV-
V110%. However, due to the limitation of retrospective
study, a larger study and a randomized trial are needed
to confirm these findings.
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